Cargando…
Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications
Cardiovascular autonomic neuropathy (CAN) is a debilitating condition that mainly occurs in long-standing type 2 diabetes patients but can manifest earlier, even before diabetes is diagnosed. CAN is a microvascular complication that results from lesions of the sympathetic and parasympathetic nerve f...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192252/ https://www.ncbi.nlm.nih.gov/pubmed/34168733 http://dx.doi.org/10.4239/wjd.v12.i6.855 |
_version_ | 1783706021982633984 |
---|---|
author | Duque, Alice Mediano, Mauro Felippe Felix De Lorenzo, Andrea Rodrigues Jr, Luiz Fernando |
author_facet | Duque, Alice Mediano, Mauro Felippe Felix De Lorenzo, Andrea Rodrigues Jr, Luiz Fernando |
author_sort | Duque, Alice |
collection | PubMed |
description | Cardiovascular autonomic neuropathy (CAN) is a debilitating condition that mainly occurs in long-standing type 2 diabetes patients but can manifest earlier, even before diabetes is diagnosed. CAN is a microvascular complication that results from lesions of the sympathetic and parasympathetic nerve fibers, which innervate the heart and blood vessels and promote alterations in cardiovascular autonomic control. The entire mechanism is still not elucidated, but several aspects of the pathophysiology of CAN have already been described, such as the production of advanced glycation end products, reactive oxygen species, nuclear factor kappa B, and pro-inflammatory cytokines. This microvascular complication is an important risk factor for silent myocardial ischemia, chronic kidney disease, myocardial dysfunction, major cardiovascular events, cardiac arrhythmias, and sudden death. It has also been suggested that, compared to other traditional cardiovascular risk factors, CAN progression may have a greater impact on cardiovascular disease development. However, CAN might be subclinical for several years, and a late diagnosis increases the mortality risk. The duration of the transition period from the subclinical to clinical stage remains unknown, but the progression of CAN is associated with a poor prognosis. Several tests can be used for CAN diagnosis, such as heart rate variability (HRV), cardiovascular autonomic reflex tests, and myocardial scintigraphy. Currently, it has already been described that CAN could be detected even during the subclinical stage through a reduction in HRV, which is a non-invasive test with a lower operating cost. Therefore, considering that diabetes mellitus is a global epidemic and that diabetic neuropathy is the most common chronic complication of diabetes, the early identification and treatment of CAN could be a key point to mitigate the morbidity and mortality associated with this long-lasting condition. |
format | Online Article Text |
id | pubmed-8192252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-81922522021-06-23 Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications Duque, Alice Mediano, Mauro Felippe Felix De Lorenzo, Andrea Rodrigues Jr, Luiz Fernando World J Diabetes Minireviews Cardiovascular autonomic neuropathy (CAN) is a debilitating condition that mainly occurs in long-standing type 2 diabetes patients but can manifest earlier, even before diabetes is diagnosed. CAN is a microvascular complication that results from lesions of the sympathetic and parasympathetic nerve fibers, which innervate the heart and blood vessels and promote alterations in cardiovascular autonomic control. The entire mechanism is still not elucidated, but several aspects of the pathophysiology of CAN have already been described, such as the production of advanced glycation end products, reactive oxygen species, nuclear factor kappa B, and pro-inflammatory cytokines. This microvascular complication is an important risk factor for silent myocardial ischemia, chronic kidney disease, myocardial dysfunction, major cardiovascular events, cardiac arrhythmias, and sudden death. It has also been suggested that, compared to other traditional cardiovascular risk factors, CAN progression may have a greater impact on cardiovascular disease development. However, CAN might be subclinical for several years, and a late diagnosis increases the mortality risk. The duration of the transition period from the subclinical to clinical stage remains unknown, but the progression of CAN is associated with a poor prognosis. Several tests can be used for CAN diagnosis, such as heart rate variability (HRV), cardiovascular autonomic reflex tests, and myocardial scintigraphy. Currently, it has already been described that CAN could be detected even during the subclinical stage through a reduction in HRV, which is a non-invasive test with a lower operating cost. Therefore, considering that diabetes mellitus is a global epidemic and that diabetic neuropathy is the most common chronic complication of diabetes, the early identification and treatment of CAN could be a key point to mitigate the morbidity and mortality associated with this long-lasting condition. Baishideng Publishing Group Inc 2021-06-15 2021-06-15 /pmc/articles/PMC8192252/ /pubmed/34168733 http://dx.doi.org/10.4239/wjd.v12.i6.855 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Duque, Alice Mediano, Mauro Felippe Felix De Lorenzo, Andrea Rodrigues Jr, Luiz Fernando Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications |
title | Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications |
title_full | Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications |
title_fullStr | Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications |
title_full_unstemmed | Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications |
title_short | Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications |
title_sort | cardiovascular autonomic neuropathy in diabetes: pathophysiology, clinical assessment and implications |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192252/ https://www.ncbi.nlm.nih.gov/pubmed/34168733 http://dx.doi.org/10.4239/wjd.v12.i6.855 |
work_keys_str_mv | AT duquealice cardiovascularautonomicneuropathyindiabetespathophysiologyclinicalassessmentandimplications AT medianomaurofelippefelix cardiovascularautonomicneuropathyindiabetespathophysiologyclinicalassessmentandimplications AT delorenzoandrea cardiovascularautonomicneuropathyindiabetespathophysiologyclinicalassessmentandimplications AT rodriguesjrluizfernando cardiovascularautonomicneuropathyindiabetespathophysiologyclinicalassessmentandimplications |